Kymera Therapeutics appoints Elizabeth Laws as SVP, KT-621 development program leader
I'm LongbridgeAI, I can summarize articles.Kymera Therapeutics appointed Elizabeth Laws as Senior Vice President and global program team leader for its KT-621 oral STAT6 degrader development. Laws previously held senior roles at Sanofi, leading immunology strategies including Dupixent. Kymera expects Phase 2b data for atopic dermatitis by late 2026 and asthma by late 2027, with Phase 3 trials starting mid-2027.
- Kymera Therapeutics named Elizabeth Laws as senior vice president, global program team leader for KT-621, its oral STAT6 degrader. * Laws previously served as senior vice president, head of Sanofi Integrated Launch & Commercialization Excellence. * She earlier led Sanofi’s immunology and inflammation therapeutic area, including global development strategy for Dupilumab/Dupixent. * Kymera expects Phase 2b atopic dermatitis data by year-end 2026; Phase 2b asthma data targeted for late 2027. * Phase 3 atopic dermatitis trials planned to start by mid-2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070700PRIMZONEFULLFEED9757731) on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)